Host Defense Mechanism-Based Rational Design of Live Vaccine

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Jang, Yo Han ^a   Byun, Young Ho ^a   Lee, Kwang Hee ^a   Park, Eun Sook ^b   Lee, Yun Ha ^a   Lee, Yoon Jae ^a   Lee, Jinhee ^a   Kim, Kyun Hwan ^b   Seong, Baik Lin ^a  

^a Yonsei University   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; INFLUENZA VACCINE; LIVE VACCINE; NONSTRUCTURAL PROTEIN 1; VIRUS NUCLEOPROTEIN; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; EMBRYO; ENZYME ACTIVATION; FEMALE; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFLUENZA VIRUS; MOUSE; MOUSE MODEL; NONHUMAN; PANDEMIC INFLUENZA; PHENOTYPE; PROTEIN CLEAVAGE; SEASONAL INFLUENZA; SIGNAL TRANSDUCTION; TEMPERATURE; VACCINATION; VIRUS ATTENUATION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS VIRULENCE; ZYGOTE;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CASPASES; CELL LINE; DOGS; FEMALE; HUMANS; INFLUENZA A VIRUS; MICE; MUTATION; NUCLEOTIDE MOTIFS; OVUM; PROTEOLYSIS; VACCINES, ATTENUATED; VIRAL PROTEINS; VIRAL VACCINES;

EID: 84884859917     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075043     Document Type: Article

References (54)

1. Chanock RM, Murphy BR, Collins PL, Coelingh KV, Olmsted RA, et al. (1988) Live viral vaccines for respiratory and enteric tract diseases. Vaccine 6: 129-133.
2. Ada GL (1990) Traditional vaccines: An overview. In: Woodrow MLaG, New Generation Vaccines. New York: Marcel Dekker. 19-29.
3. Maassab HF, Bryant ML, (1999) The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol 9: 237-244.
4. Maassab HF, DeBorde DC, (1985) Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 3: 355-369.
5. Coleman JR, Papamichail D, Skiena S, Futcher B, Wimmer E, et al. (2008) Virus attenuation by genome-scale changes in codon pair bias. Science 320: 1784-1787.
6. Lauring AS, Jones JO, Andino R, (2010) Rationalizing the development of live attenuated virus vaccines. Nat Biotech 28: 573-579.
7. Perez JT, Pham AM, Lorini MH, Chua MA, Steel J, et al. (2009) MicroRNA-mediated species-specific attenuation of influenza A virus. Nat Biotech 27: 572-576.
8. Labbe K, Saleh M, (2008) Cell death in the host response to infection. Cell Death Differ 15: 1339-1349.
9. Barber GN, (2001) Host defense, viruses and apoptosis. Cell Death Differ 8: 113-126.
10. Roulston A, Marcellus RC, Branton PE, (1999) Viruses and apoptosis. Annual Rev Microbiol 53: 577-628.
11. Lamkanfi M, Dixit VM, (2010) Manipulation of host cell death pathways during microbial infections. Cell Host Microbe 8: 44-54.
12. Galluzzi L, Brenner C, Morselli E, Touat Z, Kroemer G, (2008) Viral control of mitochondrial apoptosis. PLoS Pathog 4: e1000018.
13. Benedict CA, Norris PS, Ware CF, (2002) To kill or be killed: viral evasion of apoptosis. Nat Immunol 3: 1013-1018.
14. Steegenga WT, Riteco N, Jochemsen AG, Fallaux FJ, Bos JL, (1998) The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells. Oncogene 16: 349-357.
15. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM, (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
16. Miura M, Friedlander RM, Yuan J, (1995) Tumor necrosis factor-induced apoptosis is mediated by a CrmA-sensitive cell death pathway. Proc Natl Acad Sci U S A 92: 8318-8322.
17. Tewari M, Dixit VM, (1995) Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J Biol Chem 270: 3255-3260.
18. Chen W, Calvo PA, Malide D, Gibbs J, Schubert U, et al. (2001) A novel influenza A virus mitochondrial protein that induces cell death. Nat Med 7: 1306-1312.
19. Schultz-Cherry S, Dybdahl-Sissoko N, Neumann G, Kawaoka Y, Hinshaw VS, (2001) Influenza virus ns1 protein induces apoptosis in cultured cells. J Virol 75: 7875-7881.
20. Wurzer WJ, Planz O, Ehrhardt C, Giner M, Silberzahn T, et al. (2003) Caspase 3 activation is essential for efficient influenza virus propagation. EMBO J 22: 2717-2728.
21. Zhirnov OP, Klenk HD, (2009) Alterations in caspase cleavage motifs of NP and M2 proteins attenuate virulence of a highly pathogenic avian influenza virus. Virology 394: 57-63.
22. Zhirnov OP, Syrtzev VV, (2009) Influenza virus pathogenicity is determined by caspase cleavage motifs located in the viral proteins. J Mol Genet Med 3: 124-132.
23. Lipatov AS, Yen HL, Salomon R, Ozaki H, Hoffmann E, et al. (2008) The role of the N-terminal caspase cleavage site in the nucleoprotein of influenza A virus in vitro and in vivo. Arch Virol 153: 427-434.
24. Takizawa T, Matsukawa S, Higuchi Y, Nakamura S, Nakanishi Y, et al. (1993) Induction of programmed cell death (apoptosis) by influenza virus infection in tissue culture cells. J Gen Virol 74: 2347-2355.
25. Fesq H, Bacher M, Nain M, Gemsa D, (1994) Programmed cell death (apoptosis) in human monocytes infected by influenza A virus. Immunobiol 190: 175-182.
26. Hinshaw VS, Olsen CW, Dybdahl-Sissoko N, Evans D, (1994) Apoptosis: a mechanism of cell killing by influenza A and B viruses. J Virol 68: 3667-3673.
27. Mori I, Komatsu T, Takeuchi K, Nakakuki K, Sudo M, et al. (1995) In vivo induction of apoptosis by influenza virus. J Gen Virol 76: 2869-2873.
28. Le Goffic R, Leymarie O, Chevalier C, Rebours E, Da Costa B, et al. (2011) Transcriptomic analysis of host immune and cell death responses associated with the influenza A virus PB1-F2 protein. PLoS Pathog 7: e1002202.
29. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG, (2000) A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 97: 6108-6113.
30. Kochs G, García-Sastre A, Martínez-Sobrido L, (2007) Multiple anti-interferon actions of the influenza A virus NS1 protein. J Virol 81: 7011-7021.
31. Klumpp K, Ruigrok RWH, Baudin F, (1997) Roles of the influenza virus polymerase and nucleoprotein in forming a functional RNP structure. EMBO J 16: 1248-1257.
32. Silverman RB (1992) CHAPTER 5: Enzyme Inhibition and Inactivation. The Organic Chemistry of Drug Design and Drug Action. San Diego: Academic Press. pp. 146-219.
33. Silverman RB (1995) Mechanism-based enzyme inactivators. In: Daniel LP, editor. Methods in Enzymology: Academic Press. pp. 240-283.
34. Le TV, Mironova E, Garcin D, Compans RW, (2011) Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus. PLoS One 6: e18780.
35. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, et al. (1999) Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A 96: 9345-9350.
36. Ye Q, Krug RM, Tao YJ, (2006) The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA. Nature 444: 1078-1082.
37. Boulo S, Akarsu H, Ruigrok RWH, Baudin F, (2007) Nuclear traffic of influenza virus proteins and ribonucleoprotein complexes. Virus Res 124: 12-21.
38. Chien CY, Tejero R, Huang YP, Zimmerman DE, Rios CB, et al. (1997) A novel RNA-binding motif in influenza A virus non-structural protein 1. Nat Struct Biol 4: 891-895.
39. Bornholdt ZA, Prasad BVV, (2006) X-ray structure of influenza virus NS1 effector domain. Nat Struct Mol Biol 13: 559-560.
40. Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, et al. (1997) A combinatorial approach defines specificities of members of the caspase family and granzyme B. J Biol Chem 272: 17907-17911.
41. Nicholson DW, (1999) Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 6: 1028-1042.
42. Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, et al. (1997) Substrate specificities of caspase family proteases. J Biol Chem 272: 9677-9682.
43. Rickers A, Brockstedt E, Mapara MY, Otto A, Dorken B, et al. (1998) Inhibition of CPP32 blocks surface IgM-mediated apoptosis and D4-GDI cleavage in human BL60 Burkitt lymphoma cells. Eur J Immunol 28: 296-304.
44. Lee KH, Seo SU, Song JM, Lee CM, Kim H-A, et al. (2006) Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus. Vaccine 24: 1966-1974.
45. Belshe R, Lee M-S, Walker RE, Stoddard J, Mendelman PM, (2004) Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines 3: 643-654.
46. Damjanovic D, Small C-L, Jeyananthan M, McCormick S, Xing Z, (2012) Immunopathology in influenza virus infection: Uncoupling the friend from foe. Clin Immunol 144: 57-69.
47. Perrone LA, Plowden JK, García-Sastre A, Katz JM, Tumpey TM, (2008) H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog 4: e1000115.
48. Song M-S, Pascua PNQ, Lee JH, Baek YH, Lee O-J, et al. (2009) The polymerase acidic protein gene of influenza A virus contributes to pathogenicity in a mouse model. J Virol 83: 12325-12335.
49. Robert BB, (2004) Current status of live attenuated influenza virus vaccine in the US. Virus Res 103: 177-185.
50. Neumann G, Zobel A, Hobom G, (1994) RNA polymerase I-mediated expression of influenza viral RNA molecules. Virology 202: 477-479.
51. Stech J, Garn H, Wegmann M, Wagner R, Klenk HD, (2005) A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin. Nat Med 11: 683-689.
52. Watanabe S, Watanabe T, Kawaoka Y, (2009) Influenza a virus lacking M2 protein as a live attenuated vaccine. J Virol 83: 5947-5950.
53. Talon J, Salvatore M, O'Neill RE, Nakaya Y, Zheng H, et al. (2000) Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc Natl Acad Sci U S A 97: 4309-4314.
54. Jang YH, Seong BL, (2012) Principles underlying rational design of live attenuated influenza vaccines. Clin Exp Vaccin Res 1: 35-49.